Compounds > enkephalin--leucine-2-alanine

enkephalin--leucine-2-alanine and Arteriosclerosis-Obliterans

enkephalin--leucine-2-alanine has been researched along with Arteriosclerosis-Obliterans* in 3 studies

Trials

2 trial(s) available for enkephalin--leucine-2-alanine and Arteriosclerosis-Obliterans

Article	Year
[Dalargin in the treatment of arteriosclerosis obliterans of the lower extremities]. Sovetskaia meditsina, 1990, Issue:2 Topics: Adult; Arteriosclerosis Obliterans; Clinical Trials as Topic; Drug Evaluation; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Humans; Leg; Middle Aged; Placebos; Sympatholytics	1990
[Pathophysiological and clinical evaluation of the effectiveness of dalargin in the treatment of arterial occlusive diseases of the lower extremities]. Kardiologiia, 1990, Volume: 30, Issue:7 Eighty seven patients with Stages II-III vascular occlusions in the lower extremities were examined. The clinical and biochemical parameters of the course of the disease were found to improve in the patients who received in earlier periods dalargin supplemented to the combined therapy than in those from a matched group. There was a decrease in femoral venous blood lactate concentrations in the diseased extremity, blood cholesterol and parathyroid hormone levels. The mechanisms responsible for effects of dalargin on metabolic parameters and clinical indices of the patients' condition were also discussed. Whether it is possible to use dalargin in the combined therapy for extremity vascular occlusive diseases is considered. Topics: Adult; Anticholesteremic Agents; Arteriosclerosis Obliterans; Cholesterol; Enkephalin, Leucine-2-Alanine; Humans; Lactates; Leg; Male; Middle Aged; Parathyroid Hormone	1990

Article

Year

[Dalargin in the treatment of arteriosclerosis obliterans of the lower extremities].

Sovetskaia meditsina, 1990, Issue:2

Topics: Adult; Arteriosclerosis Obliterans; Clinical Trials as Topic; Drug Evaluation; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Humans; Leg; Middle Aged; Placebos; Sympatholytics

1990

[Pathophysiological and clinical evaluation of the effectiveness of dalargin in the treatment of arterial occlusive diseases of the lower extremities].

Kardiologiia, 1990, Volume: 30, Issue:7

Eighty seven patients with Stages II-III vascular occlusions in the lower extremities were examined. The clinical and biochemical parameters of the course of the disease were found to improve in the patients who received in earlier periods dalargin supplemented to the combined therapy than in those from a matched group. There was a decrease in femoral venous blood lactate concentrations in the diseased extremity, blood cholesterol and parathyroid hormone levels. The mechanisms responsible for effects of dalargin on metabolic parameters and clinical indices of the patients' condition were also discussed. Whether it is possible to use dalargin in the combined therapy for extremity vascular occlusive diseases is considered.

Topics: Adult; Anticholesteremic Agents; Arteriosclerosis Obliterans; Cholesterol; Enkephalin, Leucine-2-Alanine; Humans; Lactates; Leg; Male; Middle Aged; Parathyroid Hormone

1990

Other Studies

1 other study(ies) available for enkephalin--leucine-2-alanine and Arteriosclerosis-Obliterans

Article	Year
[Use of synthetic analogs of enkephalins as antiatherogenic means]. Biulleten' eksperimental'noi biologii i meditsiny, 1989, Volume: 108, Issue:10 The experiments have been performed on 70 male rats weighing 200-250 gr., 53 patients with obliterating atherosclerosis of lower extremities have been examined. Leu-enkephalin analogues (dalargin and DEFN) administration in a dose of 0.1 mg/kg has been determined to decrease cholesterol levels in the blood in acute and chronic experimental hypercholesterolemia. The use of pharmacological preparation -- enkephalin analogue of dalargin in complex treatment of the obliterating atherosclerosis of lower extremities leads to cholesterol concentration decrease, parathormone concentration decrease in the blood of patients and hyperlactatemia decrease in venous blood of the damaged extremity. Leu-enkephalin analogues, action mechanisms and the possibility of their use for atherosclerosis treatment is discussed. Topics: Adult; Animals; Arteriosclerosis Obliterans; Cholesterol; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Humans; Lactates; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Parathyroid Hormone; Rats; Rats, Inbred Strains; Sympatholytics	1989

Article

Year

[Use of synthetic analogs of enkephalins as antiatherogenic means].

Biulleten' eksperimental'noi biologii i meditsiny, 1989, Volume: 108, Issue:10

The experiments have been performed on 70 male rats weighing 200-250 gr., 53 patients with obliterating atherosclerosis of lower extremities have been examined. Leu-enkephalin analogues (dalargin and DEFN) administration in a dose of 0.1 mg/kg has been determined to decrease cholesterol levels in the blood in acute and chronic experimental hypercholesterolemia. The use of pharmacological preparation -- enkephalin analogue of dalargin in complex treatment of the obliterating atherosclerosis of lower extremities leads to cholesterol concentration decrease, parathormone concentration decrease in the blood of patients and hyperlactatemia decrease in venous blood of the damaged extremity. Leu-enkephalin analogues, action mechanisms and the possibility of their use for atherosclerosis treatment is discussed.

Topics: Adult; Animals; Arteriosclerosis Obliterans; Cholesterol; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Humans; Lactates; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Parathyroid Hormone; Rats; Rats, Inbred Strains; Sympatholytics

1989